

# Janus Henderson Global Life Sciences Fund

A Share - All data as at 31 January 2021

- The Fund may invest in any one or a combination of the following instruments:
  - futures, options and swaps and other financial derivative instruments ("FDI") for investment purposes, up to 10% of the net asset value ("NAV") of the Fund. Given the leverage effect of FDI, such investments may result in substantial loss (as much as 100% of the NAV of the relevant Fund);
  - debt securities rated below investment grade; and
  - mortgage and asset-backed securities and/or in index/structured securities. These financial instruments may be rated below investment grade.
- Investing in any one of the above instruments may involve substantial credit/counterparty, market, liquidity, currency, leverage, index, interest, swap, valuation and downgrading risks. If the issuers default, or such securities or their underlying assets, cannot be realised or perform badly, investors' entire investments may be lost.
- The Fund's investments involve developing markets. Owing to its potentially higher volatility and risk levels, as well as lower political and economic stability than developed markets, asset values could be affected in various levels.
- The Fund's investments may be more concentrated in terms of industry risk than others that diversify across industries and may therefore be subject to higher industry risk than funds with more diversified holdings.
- The investment decision is yours. If you are in any doubt about the contents of this document, you should seek independent professional financial advice.
- Investors should not only base on this document alone to make investment decisions and should read the Prospectus including the risk factors for further details.

## Investment Objective and Policy

The Fund aims to provide capital growth over the long term.

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

## Cumulative Performance (%)

	1 M	3 M	YTD	1 Yr	3 Yrs	5 Yrs	Since Launch
A2 USD share class	-1.09	14.29	-1.09	25.50	46.79	89.89	373.40
Benchmark Index	1.07	13.51	1.07	16.38	37.26	75.66	383.87

## Calendar Year Returns (%)

	2020	2019	2018	2017	2016
A2 USD share class	23.41	27.06	2.01	20.55	-13.79
Benchmark Index	13.52	23.24	2.51	19.80	-6.81

## Cumulative Return (%)



Past performance is no guarantee of future results. Source: Morningstar. Basis: total returns, NAV to NAV in USD, with income reinvested.

Source: The fund data quoted is Janus Henderson Investors unless stated otherwise. <sup>1</sup>Source of star rating: Morningstar, Inc., Sector Equity Healthcare, Class A2 USD, as of 31 January 2021.

H = hedged

## Fund Facts

Portfolio Manager	Andy Acker, CFA
Base Currency	USD
Domicile	Ireland
Benchmark Index	MSCI World Healthcare Index
Fund Size (US\$M)	\$4020.7
Dealing	Daily

## A Share

Initial Sales Charge	Up to 5.00%
Annual Management Fee	1.50%
Overall Morningstar Rating™	★★★★★ <sup>1</sup>

	A2 USD	A2 HEUR	A2 HAUD
Launch Date	31 Mar 2000	31 Mar 2000	04 Oct 2013
NAV	\$47.34	€42.14	AUD24.74
ISIN	IE0009355771	IE0002122038	IE00BF2GM042
Bloomberg	JANGLA1	JAGLA1E	JGLSAAU

	A2 HKD
Launch Date	27 Feb 2015
NAV	HKD15.78
ISIN	IE00B4R5TH58
Bloomberg	JGLSAHA

**Top 10 Holdings (%)**

AstraZeneca PLC	3.72
UnitedHealth Group Inc	3.42
AbbVie Inc	3.11
Merck & Co Inc	2.95
Novartis AG (ADR)	2.94
Roche Holding AG	2.90
Abbott Laboratories	2.48
Thermo Fisher Scientific Inc	2.46
Eli Lilly and Co	2.31
Boston Scientific Corp	2.29
<b>Total</b>	<b>28.58</b>

**Industry breakdown (%)**

Biotechnology	32.89
Pharmaceuticals	31.16
Health Care Equipment	14.52
Managed Health Care	8.04
Life Sciences Tools & Services	6.50
Health Care Supplies	3.76
Health Care Technology	1.14
Health Care Services	0.89
Health Care Facilities	0.20
Specialized Finance	0.10

**Country Breakdown (%)**

United States	81.24
Switzerland	6.24
United Kingdom	4.79
Denmark	2.23
France	1.90
Japan	1.48
Belgium	0.68
China	0.64

**Asset Allocation (%)**

US Common Stock	81.23
Non-US Common Stock	17.97
Cash & Equivalents	0.80

**Market Capitalization (%)**

Over \$100B	36.21
\$50B to \$100B	11.78
\$10B to \$50B	21.17
\$5B to \$10B	9.82
\$1B to \$5B	13.06
\$500M to \$1B	1.33
\$250M to \$500M	0.24
N/A	5.59

**Fund Characteristics**

<b>Total Number of Holdings</b>	<b>129</b>
---------------------------------	------------

Source: Janus Henderson Investors as of 31 January 2021, unless stated otherwise.

Offering documents  
can be downloaded  
here:

**Important information**

Issued in Hong Kong by Janus Henderson Investors Hong Kong Limited, licensed and regulated by the Securities and Futures Commission ("SFC"). This document has not been reviewed by the SFC. The content herein is produced for information purposes only and does not constitute investment advice or as an offer to sell, buy or a recommendation for any security. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties, in whole or in part, and do not make any warranties with regards to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance is no guarantee of future results. Investing involves risk, including the possible loss of principal and fluctuation of value.** Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from appointed intermediaries, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification. Portfolio holdings are subject to change without notice. Effective 6 July 2020, the naming convention of the Classes of Shares of the Fund has been changed. Please refer to the offering documents for more details. ©2021 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.

KH0121(24T)1221.HK.retail

**Find Out More**

General enquiries: (852) 3121 7000  
Email: [asiaclientservice@janushenderson.com](mailto:asiaclientservice@janushenderson.com)  
Website: [www.janushenderson.com](http://www.janushenderson.com)  
Or talk to your financial advisor/intermediary